128 related articles for article (PubMed ID: 9713355)
1. Microsatellite instability in ductal carcinoma in situ of the breast.
Walsh T; Chappell SA; Shaw JA; Walker RA
J Pathol; 1998 May; 185(1):18-24. PubMed ID: 9713355
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
3. Absence of microsatellite instability in breast carcinomas with both p53 and c-erbB-2 alterations.
Formantici C; Orlandi R; Ronchini C; Pilotti S; Ranzani GN; Colnaghi MI; Ménard S
J Pathol; 1999 Mar; 187(4):424-7. PubMed ID: 10398101
[TBL] [Abstract][Full Text] [Related]
4. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast.
Fujii H; Szumel R; Marsh C; Zhou W; Gabrielson E
Cancer Res; 1996 Nov; 56(22):5260-5. PubMed ID: 8912866
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast.
Vos CB; Ter Haar NT; Peterse JL; Cornelisse CJ; van de Vijver MJ
J Pathol; 1999 Feb; 187(3):279-84. PubMed ID: 10398079
[TBL] [Abstract][Full Text] [Related]
6. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.
Shen CY; Yu JC; Lo YL; Kuo CH; Yue CT; Jou YS; Huang CS; Lung JC; Wu CW
Cancer Res; 2000 Jul; 60(14):3884-92. PubMed ID: 10919664
[TBL] [Abstract][Full Text] [Related]
8. Mutation at chromosome 11q23 in human non-familial breast cancer: a microdissection microsatellite analysis.
Koreth J; Bethwaite PB; McGee JO
J Pathol; 1995 May; 176(1):11-8. PubMed ID: 7616353
[TBL] [Abstract][Full Text] [Related]
9. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
10. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
11. Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast.
Munn KE; Walker RA; Varley JM
Oncogene; 1995 Apr; 10(8):1653-7. PubMed ID: 7731721
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity in ductal carcinoma in situ of the breast.
Stratton MR; Collins N; Lakhani SR; Sloane JP
J Pathol; 1995 Feb; 175(2):195-201. PubMed ID: 7738715
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer in an MSH2 gene mutation carrier.
Westenend PJ; Schütte R; Hoogmans MM; Wagner A; Dinjens WN
Hum Pathol; 2005 Dec; 36(12):1322-6. PubMed ID: 16311127
[TBL] [Abstract][Full Text] [Related]
14. Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast.
Lininger RA; Fujii H; Man YG; Gabrielson E; Tavassoli FA
Mod Pathol; 1998 Dec; 11(12):1151-9. PubMed ID: 9872644
[TBL] [Abstract][Full Text] [Related]
15. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
16. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast.
Bock N; Meden H; Regenbrecht M; Jünemann B; Wangerin J; Marx D
Anticancer Res; 2000; 20(1A):119-24. PubMed ID: 10769643
[TBL] [Abstract][Full Text] [Related]
17. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
18. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity.
Smeds J; Wärnberg F; Norberg T; Nordgren H; Holmberg L; Bergh J
Acta Oncol; 2005; 44(1):41-9. PubMed ID: 15848905
[TBL] [Abstract][Full Text] [Related]
19. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.
Buerger H; Otterbach F; Simon R; Poremba C; Diallo R; Decker T; Riethdorf L; Brinkschmidt C; Dockhorn-Dworniczak B; Boecker W
J Pathol; 1999 Mar; 187(4):396-402. PubMed ID: 10398097
[TBL] [Abstract][Full Text] [Related]
20. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
